Berenberg Bank Reiterates Hikma Pharmaceuticals PLC

Berenberg Bank reiterated a Buy recommendation for Hikma Pharmaceuticals PLC (OTCPK:HKMPY) on November 6, 2025, setting an average one-year price target of $66.69, which implies a 33.11% upside from its $50.10 closing price. This positive analyst outlook comes despite projected annual revenue decreasing by 10.45% to $2,880 million and a non-GAAP EPS of $2.12. Institutional sentiment appears mixed, with total shares owned by institutions decreasing by 11.43% to 16K shares in the last quarter, even as the average portfolio weight of funds holding HKMPY increased by 4.90%.

Analysis

Berenberg Bank reiterated a "Buy" recommendation for Hikma Pharmaceuticals PLC (OTCPK:HKMPY) on November 6, 2025, setting an average one-year price target of $66.69/share. This target implies a significant 33.11% upside from the latest closing price of $50.10/share, reflecting strong analyst conviction. The forecast range for the stock extends from $53.42 to $80.28.

This positive analyst outlook is presented despite a projected annual revenue decrease of 10.45% to $2,880 million for HKMPY. However, the company's projected annual non-GAAP EPS is $2.12, which may suggest underlying profitability or cost management efforts offsetting revenue pressures.

Institutional investor activity shows a mixed signal, with total shares owned by institutions decreasing by 11.43% to 16K shares over the last three months. Conversely, the average portfolio weight of funds holding HKMPY increased by 4.90%, indicating a potential concentration of holdings among fewer, more committed investors. PENN MUTUAL AM 1847 INCOME FUND I notably reduced its position by 12.90% and its portfolio allocation by 4.90%.

Key Decisions for Investors

• Investors should weigh Berenberg's substantial 33.11% price target upside against the projected 10.45% decline in annual revenue.
• Closely monitor Hikma's upcoming earnings reports for details on margin resilience and cost management strategies that could support the $2.12 non-GAAP EPS despite revenue headwinds.
• Consider the nuanced institutional sentiment, where a decrease in overall institutional shares owned is juxtaposed with an increase in average portfolio weight, potentially signaling a shift towards higher conviction among a smaller set of holders.